Clinical and virological characteristics associated with severe acute hepatitis B

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages O991-O997

  Coppola, N ^a   Sagnelli, C ^b   Pisaturo, M ^c   Minichini, C ^a   Messina, V ^c   Alessio, L ^b   Starace, M ^a   Signoriello, G ^b   Gentile, I ^d   Filippini, P ^a,c   Sagnelli, E ^a  

^a Department of Medicine and Public Health   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Endocrinologia e Malattie del Ricambio   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acute hepatitis B; Fulminant hepatitis; Hepatitis C virus chronic infection; Severe acute hepatitis

Indexed keywords

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

VIRUS DNA;

ADULT; CHEMISTRY; CHRONIC HEPATITIS C; CLASSIFICATION; COMPLICATION; DEMOGRAPHY; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; MALE; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR; VIROLOGY;

ADULT; DEMOGRAPHY; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84920262898     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12720     Document Type: Article

References (31)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 14: 582-592.
2. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13: 2839-2855.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 (suppl 1): S1-S3.
4. Romanò L, Paladini S, Tagliacarne C, Zappa A, Zanetti AR. The changing face of the epidemiology of type A, B, and D viral hepatitis in Italy, following the implementation of vaccination. Vaccine 2009; 27: 3439-3442.
5. Mele A, Tosti ME, Mariano A et al. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46: 868-875.
6. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263.
7. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996; 38 (suppl 2): S39-S42.
8. Wai CT, Fontana RJ, Polson J et al. Clinical outcome and virologic characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hep 2005; 12: 192-198.
9. Kumar M, Satapathy S, Monga R et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 96-101.
10. Kusakabe A, Tanaka Y, Mochida S et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res 2009; 39: 648-656.
11. Coppola N, Tonziello G, Colombatto P et al. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect 2013; 67: 322-328.
12. Yu JW, Sun LJ, Zhao YH et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 56: 775-783.
13. Ito K, Yotsuyanag H, Yatsuhashi H et al. Risk factors for long term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 2014; 59: 89-97.
14. Garfein RS, Bower WA, Loney CM et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40: 865-873.
15. Sagnelli E, Coppola N, Pisaturo M et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49: 1090-1097.
16. Coppola N, Pisapia R, Tonziello G et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-229.
17. Sagnelli E, Pisaturo M, Stanzione M et al. Clinical presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 1174-1180.
18. Coppola N, Gentile I, Pasquale G et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014; 13: 20-26.
19. Coppola N, Potenza N, Pisaturo M et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PlosOne 2013; 8: e65336.
20. Coppola N, Marrone A, Pisaturo M et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014; 33: 559-567.
21. Andreu V, Mas A, Bruguera M et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29: 394-397.
22. Kanel GC, Cassidy W, Shuster L, Reynolds TB. Cocaine-induced liver cell injury: comparison of morphological features in man and in experimental models. Hepatology 1990; 11: 646-651.
23. Sagnelli E, Coppola N, Marrocco C et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 2006; 35: 317-320.
24. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029.
25. Sagnelli E, Coppola N, Pisaturo M et al. Clinical and virological improvement of HBV or HCV related chronic hepatitis with concomitant HAV infection. Clin Infect Dis 2006; 42: 1536-1543.
26. Smedile A, Dentico P, Zanetti A et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81: 992-997.
27. Chu CM, Liaw YF. Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. Clin Infect Dis 1995; 20: 703-705.
28. Sagnelli E, Pasquale G, Coppola N et al. Influence of chronic HBV-HCV concurrent infection on liver histology. Infection 2004; 32: 144-148.
29. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010; 51: 759-766.
30. Ozasa A, Tanaka Y, Orito E et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-334.
31. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.